# Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma

**Authors:** Albert Roessner, Sabine Franke, Julian Schreier, Sarah R. Ullmann, Franziska S. Karras

PMC · DOI: 10.3390/diagnostics15111355 · 2025-05-28

## TL;DR

This review explores how non-coding RNAs could improve the accuracy of diagnosing high-grade central osteosarcoma, a type of bone cancer.

## Contribution

The paper reviews the emerging role of non-coding RNA expression patterns as a diagnostic tool for osteosarcoma, complementing traditional histological methods.

## Key findings

- Non-coding RNA expression patterns can help distinguish between benign and malignant bone tumors.
- MicroRNA expression differences aid in differentiating osteosarcoma from other bone tumors like osteoblastoma and giant-cell tumors.
- Application of non-coding RNA diagnostics for osteosarcoma remains in early stages and requires further research.

## Abstract

A histological evaluation remains the cornerstone of diagnosing highly malignant osteosarcoma, having demonstrated its efficacy and reliability over several decades. However, despite these advancements, misdiagnoses with severe consequences, including inadequate surgical procedures, continue to occur. Consequently, there is a pressing need to further enhance diagnostic security. Adjunct immunohistochemical approaches have demonstrated significant effectiveness in regard to cancer diagnostics, generally. However, their utility for identifying highly malignant osteosarcoma is limited. Molecular genetic findings have significantly improved the diagnosis of Ewing’s sarcoma by identifying specific translocations and have been used to detect specific IDH gene mutations in chondrosarcoma. Nevertheless, molecular genetic alterations in highly malignant osteosarcoma exhibit a high degree of complexity, thereby limiting their diagnostic utility. Given that only 1–2% of the human genome comprises protein-coding sequences, the growing number of non-coding regulatory RNAs, which are increasingly being elucidated, has garnered substantial attention in the field of clinical cancer diagnostics. Over the past several years, patterns of altered non-coding RNA expression have been identified that facilitate the distinction between benign and malignant tumors in various organs. In the field of bone tumors, the experience of this approach has been limited thus far. The divergent expression of microRNAs has demonstrated utility for differentiating osteosarcoma from osteoblastoma and discriminating between osteosarcoma and giant-cell tumors of bone and fibrous dysplasia. However, the application of non-coding RNA expression patterns for the differential diagnosis of osteosarcoma is still in its preliminary stages. This review provides an overview of the current status of non-coding RNAs in osteosarcoma diagnostics, in conjunction with a histological evaluation. The potential of this approach is discussed comprehensively.

## Linked entities

- **Diseases:** osteosarcoma (MONDO:0002623), Ewing’s sarcoma (MONDO:0012817), chondrosarcoma (MONDO:0008977), fibrous dysplasia (MONDO:0000845)

## Full-text entities

- **Genes:** IDH1 (isocitrate dehydrogenase (NADP(+)) 1) [NCBI Gene 3417] {aka HEL-216, HEL-S-26, IDCD, IDH, IDP, IDPC}
- **Diseases:** Ewing's sarcoma (MESH:D012512), giant-cell tumors of bone and fibrous dysplasia (MESH:D018212), cancer (MESH:D009369), Osteosarcoma (MESH:D012516), chondrosarcoma (MESH:D002813), bone tumors (MESH:D001859), osteoblastoma (MESH:D018215)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12154195/full.md

---
Source: https://tomesphere.com/paper/PMC12154195